Helen Albert, Author at Labiotech.eu

About

Freelance science and health journalist with lots of experience writing about all aspects of life sciences and biotech. Recovering geneticist and evolutionary biologist. I am half German and half British and spend most of my time in Berlin while not hiding out in the Norfolk countryside in the UK. When not writing or editing, I like to spend my time taking photos, knitting, reading fiction, eating and making good food and travelling (when global conditions allow!).

Articles by Helen Albert

News and Trends 6 Jun 2018

Best of European Biotech at ASCO 2018

Not able to attend the biggest cancer conference of the year? No problem. We have summarized what we think are the most interesting therapy developments presented by European biotech’s at ASCO this year. Once again, the cream of the cancer specialist crop gathered in Chicago to discuss and present the latest findings in cancer research at […]

June 6, 2018 - 5 minutesmins - By Helen Albert

Interview 30 May 2018

How to Close a €3.9B Acquisition Deal for Your Biotech Company

Ablynx, one of the big giants in the European biotech arena, closed the final stages of its €3.9B acquisition deal with Sanofi earlier this month, after details were announced in January. Edwin Moses, CEO of Ablynx, shared the company’s success story with attendees at our recent Refresh Meetup in Brussels. The technology behind Ablynx’s success […]

May 30, 2018 - 7 minutesmins - By Helen Albert

News and Trends 29 May 2018

Positive House Dust Mite Immunotherapy Results for UK Biotech

British biotech Allergy Therapeutics reports positive early-stage results for its house dust mite immunotherapy. It’s been a good month for Allergy Therapeutics, which also reported positive Phase II results for its grass pollen allergy vaccine trial last week. It seems to be doing well, with a number of products targeting common allergies in late stage […]

May 29, 2018 - 1 minutemin - By Helen Albert

pili tolouse white biotechnology twb bioreactor

Interview 24 May 2018

Sugar-Munching Microbes Put the ‘Eco’ into the Dyeing Industry

The commercial dyeing industry is not known for being eco-friendly, which is something that PILI – a synbio startup based in France – is hoping to address with their color producing microbes. Philip chatted with its CEO, Jeremie Blache, to find out more about the company, its recent successful fundraising round and how its technology […]

May 24, 2018 - 5 minutesmins - By Helen Albert

More News! 18 May 2018

New Treatment for Rare Neurologic Eye Disease on Horizon from Spanish Biotech

Spanish biotech Bionure has started an early stage trial of a new drug to treat rare neurologic eye diseases, which also shows promise for treatment of multiple sclerosis and other similar conditions. The therapy (BN201) is the first its class and if successful in clinical trials will be the only treatment that can help repair […]

May 18, 2018 - 2 minutesmins - By Helen Albert

More News! 17 May 2018

After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering

Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer CropScience, for breach of a license agreement for access to patents for its TALEN technology. The French biotech Cellectis owns 79.1% of the ag biotech’s outstanding shares. Cellectis is well-known for its gene editing tool TALEN. However, while it focuses […]

May 17, 2018 - 2 minutesmins - By Helen Albert

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us